- Subscribe
- Log In More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- Basket
- Search More
Advanced search
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
Advanced search
- CloseMore
Main menu
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
- Subscribe
- Log in More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- BMJ Journals
You are here
- Home
- Archive
- Volume 83,Issue Suppl 1
- OP0193 BITEING MULTI-DRUG RESISTANT RHEUMATOID ARTHRITIS WITH CD19-T CELL ENGAGERS
Email alerts
Article Text
Article menu
- Article Text
- Article info
- Citation Tools
- Share
- Rapid Responses
- Article metrics
- Alerts
Scientific Abstracts
Oral Abstract Presentations
Clinical Abstract Sessions: Difficult-to-treat and multidrug resistant Rheumatoid Arthritis
OP0193 BITEING MULTI-DRUG RESISTANT RHEUMATOID ARTHRITIS WITH CD19-T CELL ENGAGERS
- L. Bucci1,
- M. Hagen1,
- T. Rothe1,
- M. G. Raimondo1,
- F. fa*gni1,
- C. Tur1,
- A. Wirsching1,
- J. Wacker1,
- A. Wilhelm1,
- J. P. Auger1,
- M. Eckstein1,
- S. Alivernini2,
- A. Zoli2,
- A. Bozec1,
- M. A. D’agostino2,
- G. Schett1,
- R. Grieshaber-Bouyer3
- 1Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany
- 2Fondazione Policlinico Universitario A Gemelli, IRCSS, Catholic University of Sacred Heart, Department of Rheumatology, Roma, Italy
- 3Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Medicine 3 – Rheumatology and Immunology, Erlangen, Germany
Abstract
Background: Bi-specific T-cell engagers (BiTEs) kill B cells by engaging T cells. BITEs are highly effective in acute lymphoblastic leukemia but have not yet been tested in autoimmune disease. Multi-drug resistant rheumatoid arthritis patients represent a considerable challenge and require new approaches to treat their underlying autoimmune pathology.
Objectives: Based on the action of BiTEs to kill B cells by engaging T cells as effectors we hypothesized that this principle may work also in the treatment of B cell mediated autoimmune diseases including RA.
Methods: We treated six patients with multi-drug resistant rheumatoid arthritis (RA) with two cycles of the CD19xCD3 BiTE blinatumomab via a compassionate use program. Eligibility criteria were based on (i) a diagnosis of RA according to the ACR/EULAR 2010 criteria, (ii) evidence for B cell involvement based on positivity of rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA) or presence of B cells in the synovial membrane, (iii) active disease with a disease activity score (DAS) 28 over 3.2 units and (iv) treatment resistance to methotrexate and at least three different targeted synthetic (ts) or biologic (b) disease modifying anti-rheumatic drugs (DMARDs). Changes in circulating T and B cells were measured by high dimensional spectral flow cytometry and bioinformatic analysis. Serum cytokines were measured by solid-phase chemiluminescence assay. Ultrasound was performed in all patients at baseline and at 12 week follow-up and scored according to EULAR-OMERACT. Fibroblast activation protein inhibitor (FAPI)-based positron emission tomography/computed tomography (PET-CT) was performed in one patient at baseline and follow up. Ultrasound guided synovial biopsy and immunohistochemistry for quantification of B cells and plasma cells was performed in one patient at baseline and follow up.
Results: In all six patients, blinatumomab therapy was safe and well tolerated, with brief increase in body temperature and acute phase proteins during first infusion but no signs of clinically relevant cytokine-release syndrome.
Documenting the T cell engagement function, blinatumomab induced a transient reduction of CD4+ and CD8+ T cells in the peripheral blood. Blinatumomab substantially depleted B cells in the peripheral blood. High dimensional analysis documented an immune reset with depletion of activated memory B cells, which were replaced by non-class switched, IgD positive naïve B cells. Blinatumomab lead to a rapid decline in RA clinical disease activity (mean DAS28-CRP 4.72 to 2.28 units), improved synovitis in ultrasound and FAPI-PET-CT and reduced autoantibodies. Synovial biopsy before and after two cycles of blinatumomab therapy documented a successful clearance of CD19+ B cells, CD20+ B cells and even CD138+ plasma cells in the synovial tissue, suggesting that pathologic B cell activation is interrupted.
Conclusion: These data demonstrate the principle feasibility to effectively treat B cell mediated autoimmune disease with BiTEs.
REFERENCES: NIL.
Acknowledgements: NIL.
Disclosure of Interests: None declared.
- biological DMARD
- Adaptive immunity
- Investor initiated trial
- Imaging
- ‘-omics
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- biological DMARD
- Adaptive immunity
- Investor initiated trial
- Imaging
- ‘-omics
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in using your username and password
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens